Followers | 4049 |
Posts | 152275 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Friday, September 23, 2022 1:09:37 PM
lol
Recent EVAX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/09/2024 03:00:07 PM
- Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials • GlobeNewswire Inc. • 10/09/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2024 11:00:13 AM
- Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform • GlobeNewswire Inc. • 10/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/03/2024 11:00:19 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/01/2024 08:30:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/26/2024 12:00:05 PM
- Evaxion significantly expands vaccine development collaboration with MSD • GlobeNewswire Inc. • 09/26/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2024 08:30:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 12:30:06 PM
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 11:30:06 AM
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 12:24:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 12:22:02 PM
- Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01 • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 • GlobeNewswire Inc. • 09/09/2024 11:00:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/23/2024 12:30:32 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/23/2024 04:15:03 AM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 08/20/2024 12:45:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 09:31:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 11:15:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 11:00:39 AM
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/12/2024 11:45:07 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM